5 active not recruiting, 1 terminated. 4 Phase 2, 2 Phase 1, 2 Phase 3.
By phase and status
Follow this drug Literature Review of Livmoniplimab trials Research Report on Livmoniplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) Livmoniplimab, Budigalimab, Docetaxel - Urothelial Carcinoma Phase 2 Active not recruiting AbbVie 150 2025-01-20 2025-08-11 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab - Hepatocellular Carcinoma (HCC) Phase 1 Terminated AbbVie 3 2024-09-11 2026-10-21 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Livmoniplimab, Budigalimab, Pembrolizumab - Non-Small Cell Lung Cancer Phase 2 / Phase 3 Active not recruiting AbbVie 167 2024-04-10 2026-10-19 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab, Durvalumab - Hepatocellular Carcinoma Phase 2 / Phase 3 Active not recruiting AbbVie 89 2024-01-11 2026-09-22 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) Budigalimab, Livmoniplimab, Lenvatinib - Hepatocellular Carcinoma Phase 2 Active not recruiting AbbVie 130 2023-09-21 2025-08-14 Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors Livmoniplimab, Budigalimab - Advanced Solid Tumors Cancer Phase 1 Active not recruiting AbbVie 364 2019-02-21 2025-05-25
Conditions studied Carcinoma, Hepatocellular (4) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Sponsors AbbVie (6)
Countries France (5) · Spain (5) · United States (5) · Japan (4) · Taiwan (4) · Israel (3) · Italy (3) · Puerto Rico (3) · South Korea (3) · Australia (2) · Belgium (2) · Canada (2) · Poland (2) · Chile (1) · China (1)
Results publications PMID 39534099
NIH funding 2023 (3)